    [Congressional Record Index (1998)]
    [From the U.S. Government Publishing Office, www.gpo.gov]

    PHARMACEUTICALS related term(s) Drugs
      Articles and editorials
        Medications From Mexico, S7261 [26JN]
      Bills and resolutions
        Controlled Substances Act:  civil liability for illegal
            manufacturers and distributors of controlled substances, (see
            H.R. 4204), H5492 [14JY]
        DEA:  assessment of fines on pharmacies for record keeping
            violations, (see S. 2600), S12164 [9OC]
        Dept. of HHS:  ensure individuals who undertake federally funded
            research and development of drugs enter into pricing agreements,
            (see H.R. 3758), H2605 [29AP]
        Diseases:  Medicare coverage and research funding for amyotrophic
            lateral sclerosis, (see S. 2265), S7574 [7JY]
        Drugs:  distribution chain of prescription drugs, (see H.R. 4024),
            H4325 [9JN]
        ------ limit amount of controlled substances allowed to be brought
            into the U.S. from Mexico and Canada, (see S. 2242), S7255
            [26JN]
        ------ provided incentives for the development of medications to
            treat drug addiction, (see S. 2015), S3919 [30AP]
        ------ rescheduling of certain drugs which pose a danger to public
            safety, (see S. 2014), S3919 [30AP]
        ------ rescheduling of flunitrazepam into schedule I of the
            Controlled Substances Act, (see H.R. 3093), H62 [27JA]
        ------ restrict disclosure of prescription information by pharmacy
            owners, pharmacists, and other pharmacy employees, (see H.R.
            3756), H2605 [29AP]
        ------ support existing Federal legal process for determining safety
            and efficacy of using marijuana and other drugs for medicinal
            purposes, (see S.J. Res. 56), S10657 [21SE], (see S.J. Res. 57),
            S10657 [21SE]
        ------ use of marijuana for medicinal purposes, (see H.J. Res. 117),
            H2706 [30AP]
        FDA:  establish therapeutic equivalence requirements for generic
            drugs, (see H.R. 4849), H11042 [16OC]
        ------ require notification of recalls of drugs and devices, (see S.
            1767), S1990 [16MR], (see H.R. 3462), H1158 [12MR]
        Foreign trade:  limit controlled substances from Mexico, (see H.R.
            3633), H2052 [1AP]
        Insurance:  coverage of prescription drugs, (see H.R. 4559), H7690
            [14SE]
        Medicare:  clarify non-preemption of State prescription drug benefit
            laws relative to Medicare+Choice plans, (see H.R. 4648), H9084
            [26SE]
        ------ coverage of outpatient prescription drugs and home infusion
            drug therapy, (see H.R. 4753), H10076 [8OC]
        ------ ensure access to comparable prescription drug coverage in
            Medigap policies relative to termination of Medicare+Choice
            plans, (see H.R. 4862), H11695 [20OC]
        ------ exempt licensed pharmacists from surety bond requirements for
            suppliers of durable medical equipment, (see S. 1680), S1003
            [25FE], (see H.R. 3284), H676 [26FE]
        ------ limit payments for drugs or biological products, (see H.R.
            3139), H240 [3FE]
        ------ reductions in prescription drug prices, (see H.R. 4627),
            H8931 [25SE], (see H.R. 4646), H9083 [26SE], (see H.R. 4794),
            H10513 [10OC]
        NIH:  establish National Center for Complementary and Alternative
            Medicine, (see S. 2420), S9556 [31JY]
        Prescription Drug Price Monitoring Commission:  establish, (see H.R.
            3925), H3742 [21MY]
        Tariff:  anti-cancer drugs, (see H.R. 3386, S. 1936), S3217 [3AP],
            (see S. 1937), S3218 [3AP], (see S. 1938), S3218 [3AP], (see S.
            1939), S3218 [3AP], (see S. 1940), S3218 [3AP], (see S. 1941),
            S3218 [3AP], (see S. 1944), S3218 [3AP], (see S. 1945), S3218
            [3AP], H903 [5MR], (see H.R. 3387), H903 [5MR]
        ------ anti-HIV and anti-AIDS drug production, (see H.R. 3328, S.
            1810), S2424 [23MR], H850 [4MR], (see H.R. 3385), H903 [5MR]
        ------ HIV antiviral drug production, (see H.R. 3384, S. 1946),
            S3218 [3AP], (see S. 1947), S3218 [3AP], (see S. 1948), S3218
            [3AP], (see S. 1949), S3218 [3AP], (see S. 1950), S3218 [3AP],
            (see S. 1951), S3218 [3AP], (see S. 1952), S3218 [3AP], (see S.
            1953), S3218 [3AP], (see S. 1954), S3218 [3AP], (see S. 1955),
            S3218 [3AP], (see S. 1956), S3218 [3AP], (see S. 2399), S9556
            [31JY], H903 [5MR], (see H.R. 3388), H903 [5MR], (see H.R.
            3389), H903 [5MR], (see H.R. 3390), H903 [5MR], (see H.R. 3391),
            H903 [5MR], (see H.R. 3392), H903 [5MR], (see H.R. 3393), H903
            [5MR], (see H.R. 3394), H903 [5MR], (see H.R. 3428), H1020
            [10MR], (see H.R. 3429), H1021 [10MR], (see H.R. 3477), H1236
            [17MR], (see H.R. 4190), H5404 [25JN], (see H.R. 4191), H5404
            [25JN]
        ------ HIV protease inhibitor production, (see S. 1942), S3218
            [3AP], (see S. 1943), S3218 [3AP]
        Taxation:  treatment of excise tax on vaccines, (see S. 2118), S5434
            [22MY]
        WHO:  encourage the U.S. becoming a signatory to the Guidelines for
            Drug Donations, (see H. Con. Res. 225), H677 [26FE]
      Excerpts
        Next Ten Years of Health Spending--What Does the Future Hold?, E2101
            [12OC]
      Letters
        Controlled Substances Trafficking Prohibition Act:  Representative
            Bliley, Committee on Commerce (House), H6903 [3AU]
        ----- Representative Hyde, Committee on the Judiciary (House), H6903
            [3AU]
        Human Cloning Prohibition Act:  Alan F. Holmer, Pharmaceutical
            Research and Manufacturers of America, S578 [10FE]
        ------ William L. Respess, Ligand Pharmaceuticals (company), S579
            [10FE], S580 [10FE]
        Licensed pharmacists' exemption from surety bond requirements for
            suppliers of durable medical equipment under Medicare:  Galen
            Jordre, North Dakota Pharmaceutical Association, S1013 [25FE]
        ----- John A. Gans, American Pharmaceutical Association, S1013
            [25FE]
        ----- John M. Rector, National Community Pharmacists Association,
            S1013 [25FE]
        Prescription drug prices, E138 [11FE]
        Support existing Federal legal process for determining safety and
            efficacy of using marijuana and other drugs for medicinal
            purposes:  Barry R. McCaffrey, Office of National Drug Control
            Policy, S10665 [21SE]
      Proposals
        Support existing Federal legal process for determining safety and
            efficacy of using marijuana and other drugs for medicinal
            purposes:  Committee on the Judiciary (House), H7725 [15SE]
      Remarks in House
        Cleveland, OH:  quality of life in neighborhoods relative to
            acquisition of properties by Rite Aid Corp., H5070 [24JN]
        Dept. of Defense:  include certain beneficiaries in National Mail
            Order Pharmacy Program, H3466 [19MY]
        ------ viagra funding, H10672 [13OC]
        Dept. of HHS:  ensure individuals who undertake federally funded
            research and development of drugs enter into pricing agreements
            (H.R. 3758), E2065 [11OC]
        Diseases:  Medicare coverage and research funding for amyotrophic
            lateral sclerosis (H.R. 2009), H1623 [26MR]
        Drugs:  civil liability for illegal manufacturers and distributors
            of controlled substances, H7884 [16SE], H7885 [16SE]
        ------ exclusivity periods for medications to treat drug addiction,
            H7860-H7863 [16SE], H7870 [16SE]
        ------ limit amount of controlled substances allowed to be brought
            into the U.S. from Mexico (H.R. 3633), H6903-H6906 [3AU]
        ------ support existing Federal legal process for determining safety
            and efficacy of using marijuana and other drugs for medicinal
            purposes (H.J. Res. 117), H7719-H7726 [15SE]
        Federal Employees Health Benefits Program:  coverage of
            abortifacients, H5719-H5722 [16JY]
        ------ coverage of contraceptives under any plan providing
            prescription drug coverage, H5568 [15JY], H5569 [15JY], H5571
            [15JY], H5677-H5684 [16JY], H5694-H5697 [16JY], H5865 [20JY],
            E1346 [17JY]
        ------ coverage of contraceptives under any plan providing
            prescription drug coverage, H9184 [29SE], H9190 [1OC], H9339
            [2OC], H9914-H9919 [7OC], H9928-H9932 [7OC]
        Foreign trade:  limit controlled substances from Mexico (H.R. 3633),
            E569 [2AP]
        Medicare:  coverage of outpatient prescription drugs and home
            infusion drug therapy (H.R. 4753), E1956 [8OC], E1969 [8OC],
            E1980 [9OC], E2101 [12OC]
        ------ exempt licensed pharmacists from surety bond requirements for
            suppliers of durable medical equipment, H614 [25FE]
        ------ limit payments for drugs or biological products (H.R. 3139),
            H302 [4FE]
        ------ reductions in prescription drug prices (H.R. 4627), H10920
            [15OC], E1898 [2OC], E2060 [11OC], E2061 [11OC], E2065 [11OC]
        ------ reductions in prescription drug prices (H.R. 4646), H9182
            [29SE], H9183 [29SE], H9195-H9201 [1OC], H9352 [5OC], E1866
            [1OC], E1869 [1OC], E1893 [2OC], E2059 [11OC], E2060 [11OC]
        ------ treatment of prescription drugs (H.R. 4627), H9163 [28SE]
        National Community Pharmacists Association:  anniversary, E2252
            [20OC]
        Prescription Drug Price Monitoring Commission:  establish (H.R.
            3925), H4231 [5JN]
        Schering-Plough Corp.:  patent extension for certain
            pharmaceuticals, E2121 [13OC]
        Senior citizens:  establish a program of pharmacy assistance fee for
            elderly persons who have no health insurance coverage (H.R.
            2681), E2060 [11OC]
      Remarks in Senate
        Arms Export Control Act:  exempt medicines and medical equipment
            from the application of sanctions, S7813 [9JY]
        Contraceptives:  require equitable coverage of drugs, devices, and
            services under health insurance plans (S. 743), S4772 [13MY]
        DEA:  assessment of fines on pharmacies for record keeping
            violations, S8876 [23JY]
        ------ assessment of fines on pharmacies for record keeping
            violations (S. 2600), S12168 [9OC]
        Diseases:  Medicare coverage and research funding for amyotrophic
            lateral sclerosis (S. 2265), S7575 [7JY]
        ------ prostate cancer research programs funding, S8442 [17JY]
        ------ tribute to cooperative initiatives between pharmaceutical
            companies and Federal Government to combat infectious diseases
            worldwide, S276 [2FE]
        Drugs:  limit amount of controlled substances allowed to be brought
            into the U.S. from Mexico and Canada (S. 2242), S7260 [26JN]
        ------ limit amount of controlled substances allowed to be brought
            into the U.S. from Mexico (H.R. 3633), S12680 [20OC], S12681
            [20OC]
        ------ provide incentives for the development of medications to
            treat drug addiction (S. 2015), S3932 [30AP]
        ------ rescheduling of certain drugs which pose a danger to public
            safety (S. 2014), S3931 [30AP]
        ------ support existing Federal legal process for determining safety
            and efficacy of using marijuana and other drugs for medicinal
            purposes (S.J. Res. 56), S10665-S10667 [21SE], S10673 [22SE],
            S10713 [22SE] support existing Federal legal process for
            determining safety and efficacy of using marijuana and other
            drugs for medicinal purposes (S.J. Res. 57), S10665-S10667
            [21SE]
        FDA:  Office of Generic Drugs funding, S8120 [14JY]
        ------ orphan products research funding, S8099 [14JY]
        ------ reform testing and approval process for certain generic
            drugs, S12846 [21OC]
        ------ require notification of recalls of drugs and devices (S.
            1767), S1995 [16MR]
        Federal Employees Health Benefits Program:  coverage of
            contraceptives under any plan providing prescription drug
            coverage, S9193-S9199 [29JY]
        ------ coverage of contraceptives under any plan providing
            prescription drug coverage, S11681 [7OC], S12135 [9OC], S12136
            [9OC]
        Foreign policy:  exempt agricultural products, medicines, and
            medical equipment from unilateral economic sanctions,
            S8214-S8228 [15JY]
        ----- exempt agricultural products, medicines, and medical equipment
            from unilateral economic sanctions except to countries
            sponsoring international terrorism, S8226-S8228 [15JY]
        Henney, Jane:  nomination to be FDA Commissioner, S7031 [24JN]
        Medicare:  exempt licensed pharmacists from surety bond requirements
            for suppliers of durable medical equipment (S. 1680),
            S1012-S1014 [25FE]
        NIH:  establish National Center for Complementary and Alternative
            Medicine (S. 2420), S9593 [31JY]
        Tariff:  anti-cancer drugs (S. 1936), S3219 [3AP]
        ------ anti-cancer drugs (S. 1937), S3219 [3AP]
        ------ anti-cancer drugs (S. 1938), S3219 [3AP]
        ------ anti-cancer drugs (S. 1939), S3219 [3AP]
        ------ anti-cancer drugs (S. 1940), S3219 [3AP]
        ------ anti-cancer drugs (S. 1941), S3219 [3AP]
        ------ anti-cancer drugs (S. 1944), S3219 [3AP]
        ------ anti-cancer drugs (S. 1945), S3219 [3AP]
        ------ anti-HIV and anti-AIDS drug production (S. 1810), S2429
            [23MR]
        ------ HIV antiviral drug production (S. 1946), S3219 [3AP]
        ------ HIV antiviral drug production (S. 2399), S9560 [31JY]
        ------ HIV protease inhibitor production (S. 1942), S3219 [3AP]
        ------ HIV protease inhibitor production (S. 1943), S3219 [3AP]
        Taxation:  treatment of excise tax on vaccines (S. 2118), S5447
            [22MY]
        Women:  release of study on abuse of alcohol, cigarettes, and
            psychoactive prescription drugs by older women, S5658 [4JN]
      Reports
        Drug Pricing in the 9th Congressional District of Tennessee--Drug
            Companies Profit at the Expense of Older Americans:  Committee
            of Government Reform and Oversight (House), E2062-E2065 [11OC]
      Reports filed
        Limit Amount of Controlled Substances Allowed To Be Brought Into the
            U.S. From Mexico:  Committee on the Judiciary (House) (H.R.
            3633) (H. Rept. 105-629), H5735 [16JY]
      Summaries
        Medicare Coverage of Outpatient Prescription Drugs and Home Infusion
            Drug Therapy (H.R. 4753), E1957 [8OC]
      Tables
        Federal cost of illustrative Medicare benefits package including
            prescription drug and stop-loss coverage, E1981 [9OC]
        Federal cost of Medicare drug coverage under alternative cost
            sharing requirements with Medicaid offsets, E1981 [9OC]
        Prescription drug benefit costs for SMI enrollees, E1981 [9OC]
        Prescription drug price differentials, H9183 [29SE]
      Texts of
        H.J. Res. 117, support existing Federal legal process for
            determining safety and efficacy of using marijuana and other
            drugs for medicinal purposes, H7719 [15SE]
        H.R. 3633, Controlled Substances Trafficking Prohibition Act, H6903
            [3AU]
        S. 1680, exempt licensed pharmacists from surety bond requirements
            for suppliers of durable medical equipment under Medicare, S1013
            [25FE]
        S. 1767, Drug and Device Recall Reporting Act, S1995 [16MR]
        S. 1810, tariff on anti-HIV and anti-AIDS drug production, S2429
            [23MR]
        S. 1936, tariff on anti-cancer drugs, S3220 [3AP]
        S. 1937, tariff on anti-cancer drugs, S3220 [3AP]
        S. 1938, tariff on anti-cancer drugs, S3220 [3AP]
        S. 1939, tariff on anti-cancer drugs, S3220 [3AP]
        S. 1940, tariff on anti-cancer drugs, S3221 [3AP]
        S. 1941, tariff on anti-cancer drugs, S3221 [3AP]
        S. 1942, tariff on HIV protease inhibitor production, S3221 [3AP]
        S. 1943, tariff on HIV protease inhibitor production, S3221 [3AP]
        S. 1944, tariff on anti-cancer drugs, S3221 [3AP]
        S. 1945, tariff on anti-cancer drugs, S3221 [3AP]
        S. 1946, tariff on HIV antiviral drug production, S3221 [3AP]
        S. 2265, Amyotrophic Lateral Sclerosis (ALS) Research, Treatment,
            and Assistance Act, S7575 [7JY]
        S. 2399, tariff on HIV antiviral drug production, S9560 [31JY]